In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI-01, while building the next generation of genomic medicines to address ...
Check out what similar properties have sold for in this area.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback